Our results suggested that HER2+ patients were more likely to have increased TIM-3 expressions on cytotoxic CD8- T cells, and patients with a younger age and advanced tumor burden are more likely to express ICRs on TILs compared to others. This evidence concerns the gene ERBB2 and neoplasm.